Peringatan Keamanan

No data are available regarding overdosage of tarlatamab.

Tarlatamab

DB17256

biotech approved investigational

Deskripsi

Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer.^L50748 It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed across various SCLC disease stages and treatment statuses.L50743,A263808 Its bispecificity causes T-cell activation, the release of inflammatory cytokines, and lysis at DLL3-expressing cells.^L50743

Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,L50743,L50748 becoming the first DLL3-targeting bispecific T-cell engager to receive marketing approval.^A263808

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) The median terminal half-life of tarlatamab-dlle is 11.2 days.[L50743]

Volume Distribusi At steady-state, the volume of distribution of tarlatamab-dlle is 8.6 liters.[L50743]

Klirens (Clearance) The systemic clearance of tarlatamab-dlle in patients with SCLC is 0.65 L/day.[L50743]

Absorpsi

Tarlatamab is administered intravenously and therefore has an effective bioavailability of 100%.^L50743 Following the first step-up dose of 1 mg, the geometric mean C_avg was 102 ng/mL, the geometric mean C_max was 285, and the geometric mean C_trough was 47 ng/mL.^L50743 At steady-state, with the administration of 10 mg every 2 weeks, the geometric mean C_avg was 1040 ng/mL, the geometric mean C_max was 3400, and the geometric mean C_trough was 495 ng/mL.^L50743

Metabolisme

As with other therapeutic proteins, tarlatamab-dlle is likely metabolized into smaller peptides and amino acids by non-specific catabolic pathways.^L50743

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

0 Data

Tidak ada data.

Target Protein

Delta-like protein 3 DLL3

T-cell surface glycoprotein CD3 CD3D

Referensi & Sumber

Artikel (PubMed)

PMID: 38730427
Su PL, Chakravarthy K, Furuya N, Brownstein J, Yu J, Long M, Carbone D, Li Z, He K: DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. Mol Cancer. 2024 May 10;23(1):97. doi: 10.1186/s12943-024-02012-z.
PMID: 37577302
Addeo A, Banna GL, Friedlaender A: Tarlatamab: a potential new option for recurrent small cell lung cancer. Transl Lung Cancer Res. 2023 Jul 31;12(7):1628-1630. doi: 10.21037/tlcr-23-215. Epub 2023 Jun 5.

Link

Contoh Produk & Brand

Produk: 4 • International brands: 0

Produk

Imdelltra

Powder, for solution • 1 mg / vial • Intravenous • Canada • Approved
Imdelltra

Powder, for solution • 10 mg / vial • Intravenous • Canada • Approved
Imdelltra (amg757)

Injection, powder, lyophilized, for solution; Kit • 0.9 mg/1mg • Intravenous • US • Approved
Imdelltra (amg757)

Injection, powder, lyophilized, for solution; Kit • 2.4 mg/1mg • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.